These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36174024)

  • 1. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma.
    Wang X; Katz S; Miura J; Karakousis G; Roshkovan L; Walker S; McNulty S; Ciunci C; Cengel K; Langer CJ; Marmarelis ME
    PLoS One; 2022; 17(9):e0275187. PubMed ID: 36174024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
    Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
    Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
    Ann Surg Oncol; 2024 Jan; 31(1):556-566. PubMed ID: 37940804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
    Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.
    Kepenekian V; Péron J; You B; Bonnefoy I; Villeneuve L; Alyami M; Bakrin N; Rousset P; Benzerdjeb N; Glehen O
    Ann Surg Oncol; 2022 Mar; 29(3):2104-2113. PubMed ID: 34713369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 8. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
    Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
    Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
    Marmarelis ME; Wang X; Roshkovan L; Grady CB; Miura JT; Ginsberg MS; Ciunci CA; Egger J; Walker S; Cercek A; Foote MB; Litzky LA; Nash G; Haas AR; Karakousis GC; Cengel KA; Katz SI; Zauderer MG; Langer CJ; Offin M
    JAMA Netw Open; 2023 Mar; 6(3):e232526. PubMed ID: 36897589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution.
    Orbach D; André N; Brecht IB; López Almaraz R; Ben-Ami T; Vermersch S; Carton M; Virgone C; Bisogno G; Schneider DT; Bajciova V; Reguerre Y; Galateau-Salle F; Stachowicz-Stencel T; Dvir R; Rees H; Bien E; Ferrari A; Ben Arush M
    Eur J Cancer; 2020 Nov; 140():63-70. PubMed ID: 33049597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
    Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
    Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series.
    Leinwand JC; Taub RN; Chabot JA; Kluger MD
    Ann Surg Oncol; 2020 Jul; 27(7):2539-2547. PubMed ID: 31832913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.